Piper Sandler downgraded Core Labs from Neutral to Underweight and set a new price target of $21.30 from $19.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
| 4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
| 1/9/2023 | Underperform → Neutral | BofA Securities | |
| 10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
| 9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
| 4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
| 1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
| 12/7/2021 | $34.00 → $32.00 | Equal-Weight | Morgan Stanley |
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on October 23rd and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
SCHEDULE 13G - Core Laboratories Inc. /DE/ (0001958086) (Subject)
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on October 23rd and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
BofA Securities upgraded Core Labs from Underperform to Neutral
Core Laboratories (NYSE:CLB) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $130.577 million which missed the analyst consensus estimate of $132.170 million by 1.21 percent. This is a 2.11 percent increase over sales of $127.881 million the same period last year.
B of A Securities analyst Chase Mulvehill maintains Core Laboratories (NYSE:CLB) with a Underperform and lowers the price target from $16 to $15.